What is PTC Therapeutics's SG&A?

PTC Therapeutics (PTCT) reported SG&A of $86.18M in Q1 2026.

How has PTC Therapeutics's SG&A changed year-over-year?

PTC Therapeutics's SG&A increased by 6.5% year-over-year, from $80.96M to $86.18M.

What is the long-term trend for PTC Therapeutics's SG&A?

Over 4 years (2021 to 2025), PTC Therapeutics's SG&A has grown at a 5.0% compound annual growth rate (CAGR), from $285.77M to $347.14M.

Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

PTC Therapeutics PTCT SG&A

SG&A at other companies

BioMarin PharmaceuticalsBMRN

$258.29M+25.3%

BridgeBio PharmaBBIO

$163.9M+54.1%

United TherapeuticsUTHR

$184.1M+8.2%

BiogenBIIB

$607.3M+6.1%

ALN

Alnylam PharmaceuticalsALNY

——

Arrowhead ResearchARWR

——

Other financials

Income statement

See full

Revenue$272.6M-76.8%

Operating income$45.0M-95.4%

Net income-$2.8M-100%

EPS (diluted)-$0.03-100%

Balance sheet

See full

Cash & equivalents$834.0M-43.7%

Total debt$395.1M+0.1%

Total equity-$180.5M+2.9%

Total assets$2.9B+8.0%

Cash flow

See full

Operating cash flow-$59.0M-107%

CapEx$1.2M-30.6%

Free cash flow-$60.2M-107%

Valuation

See full

Market cap$6.55B+40.3%

Enterprise value$6.11B+77.3%

P/E8×—

P/S7.9×+5.3×

Profitability

See full

Gross margin96%—

Operating margin1.6%-38.7pp

Net margin42.3%+27.4pp

FCF margin39.1%+32.8pp

Returns & leverage

See full

Return on equity-216.7%—

Debt / equity372.3×—

Current ratio2.4×-1.5×

Where this comes from

Reported directly by PTC Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: PTC Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about PTC Therapeutics's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is PTC Therapeutics's SG&A?: PTC Therapeutics (PTCT) reported SG&A of $86.18M in Q1 2026.
How has PTC Therapeutics's SG&A changed year-over-year?: PTC Therapeutics's SG&A increased by 6.5% year-over-year, from $80.96M to $86.18M.
What is the long-term trend for PTC Therapeutics's SG&A?: Over 4 years (2021 to 2025), PTC Therapeutics's SG&A has grown at a 5.0% compound annual growth rate (CAGR), from $285.77M to $347.14M.
What does SG&A mean?: Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.